Amoxicillin

Generic Name: Amoxicillin

Brand Names: Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₉N_₃O_₅S

CAS Number: 26787-78-0

Unique Ingredient Identifier: 9EM05410Q9

Background: Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.

Amoxicillin was granted FDA approval on 18 January 1974.

Indication: Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.

Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections

Clinical Trials

Amoxicillin for Enteral Nutrition Intolerance in Pediatric Intensive Care Unit

Phase 2

Recruiting

Conditions: Enteral Feeding Intolerance

Interventions: Drug: Amoxicillin
Other: Placebo

First Posted Date: 2023-04-25

Last Posted Date: 2023-04-26

Lead Sponsor: Sohag University

Target Recruit Count: 90

Registration Number: NCT05828758

Locations: 🇪🇬
Pediatric Intensive Care Unit - Sohag University Hospital, Sohag, Egypt

Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics

Phase 4

Recruiting

Conditions: Laparoscopic Appendectomy
Complicated Appendicitis
Periappendicular Abscess

Interventions: Drug: Amoxicillin clavulanic acid IV during hospitalization
Drug: Amoxicillin clavulanic acid IV 3 days and PO until day 5

First Posted Date: 2023-03-09

Last Posted Date: 2023-03-31

Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Target Recruit Count: 158

Registration Number: NCT05761080

Locations: 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology

Phase 4

Recruiting

Conditions: Gastric Cancer
Peptic Ulcer
Gastritis
Dyspepsia
Helicobacter Pylori Infection

Interventions: Drug: Esomeprazole
Drug: Bismuth
Drug: Amoxicillin
Drug: Clarithromycin

First Posted Date: 2023-02-24

Last Posted Date: 2023-11-14

Lead Sponsor: Xijing Hospital of Digestive Diseases

Target Recruit Count: 120

Registration Number: NCT05742568

Locations: 🇨🇳
Xijing Hosipital of Digestive Disease, Xi'an, Shaanxi, China

Efficacy of Therapy Based on Fecal Molecular Antimicrobial Susceptibility Tests for Helicobacter Pylori Infection

Phase 4

Recruiting

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Rabeprazole
Drug: Colloidal Bismuth Pectin Granules
Drug: Amoxicillin
Drug: Clarithromycin
Drug: Furazolidone

First Posted Date: 2023-02-08

Last Posted Date: 2023-05-15

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 855

Registration Number: NCT05718609

Locations: 🇨🇳
Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, Zhejiang, China

Evaluation of the Effect of Systemic Proteolytic Enzyme Therapy on Postoperative Inflammatory Response and QoL After Surgical Extraction of Impacted Mandibular Third Molars

Phase 3

Recruiting

Conditions: Post Operative Pain

Interventions: Drug: systemic proteolytic enzyme (Tibrolin)
Drug: Amoxicillin 500mg+metronidazole 500mg+ doliprane 100mg

First Posted Date: 2023-01-12

Last Posted Date: 2024-05-08

Lead Sponsor: University of Baghdad

Target Recruit Count: 55

Registration Number: NCT05681312

Locations: 🇮🇶
Dunya Abdulmuniem Mahmood, Baghdad, Iraq

The Effect of Probiotics on Gut Microbiotain After Helicobacter Pylori Eradication

Phase 4

Not yet recruiting

Conditions: Helicobacter Pylori Infection
Infections
Intestinal Bacteria Flora Disturbance

Interventions: Drug: Vonoprazan
Drug: Amoxicillin
Drug: probiotics

First Posted Date: 2022-12-20

Last Posted Date: 2023-02-08

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 100

Registration Number: NCT05658055

Locations: 🇨🇳
Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China

Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori

Phase 4

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Vonoprazan
Drug: Amoxicillin

First Posted Date: 2022-12-14

Last Posted Date: 2024-11-19

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 900

Registration Number: NCT05649540

Locations: 🇨🇳
Changzhou Traditional Chinese Medicine Hospital, Changzhou, Jiangsu, China
🇨🇳
Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳
The Affiliated Zhangjiagang Hospital of Soochow University, Zhangjiagang, Jiangsu, China

and more 10 locations